Albuvirtide vs Lipovirtide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV gp41 · full HIV pipeline

Albuvirtide · Aikening

Marketed by Frontier Biotechnologies

Phase 3 in HIVPeptide (fusion inhibitor)
Partial signal

NCT02369965 · Phase 3 · completed

The study randomly assigned 418 participants to an active comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: July 2028 · NCT07727642 (registry estimate)

Reported efficacy

Percentage of participants of virological suppression at Week 48 (Through Week 48): Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met. (met)

Result source: NCT02369965

Lipovirtide

Developed by Shanxi Kangbao Biological Product

Phase 2 in HIVPeptide (fusion inhibitor)
Partial signal

NCT06061536 · Phase 2 · completed

The study was randomized and included an active DTG comparator, but it was open-label, enrolled 64 participants across four groups, and used viral suppression as a surrogate laboratory endpoint rather than a hard clinical outcome. Because the primary comparison and its statistical result are not available, the findings cannot be judged as having met or missed the endpoint.

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlbuvirtideLipovirtide
HIV-1 RNA below 50 copies/mL (week 48)—Not posted · NCT02369965—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT02369965—Not reported
CD4 count, change (week 48)—Not posted · NCT02369965—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Albuvirtide
—Not posted · NCT02369965
Lipovirtide
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Albuvirtide
—Not posted · NCT02369965
Lipovirtide
—Not reported

CD4 count, change (week 48)

Albuvirtide
—Not posted · NCT02369965
Lipovirtide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lipovirtide: no structured comparison results are available for HIV.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Albuvirtide

Virologic Suppression 80.4% vs 66% NRTI+LPV/r control @ 48wk
responder rate · % of participants
NCT02369965 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuvirtide's landscape · Lipovirtide's landscape